TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28114648
Drug: Provider intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provider intervention (electronic delivery of patient-specific osteoarthritis treatment recommendations)
Study: 23340519
Drug: 8-week MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-week MPH treatment (follow-up for 7 patients)
Study: 10626860
Drug: 0.2% GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% GTN ointment
Study: 11339416
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT2) for 2 weeks
Study: 11339416
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT3) for 3 weeks
Study: 11072531
Drug: ISDN-SR 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN-SR 480 mg a day (4-times-daily)
Study: 7659429
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments (including anxiolytics)
Study: 1657528
Drug: Lidoflazine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidoflazine (calcium entry blocker) administered intravenously after restoration of spontaneous circulation
Study: 30365356
Drug: High-dose iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose iron sucrose (400 mg monthly)
Study: 29991700
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (MT)
Study: 27483130
Drug: Guanfacine immediate-release
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine immediate-release (GUAN-IR) 1-3 mg/day
Study: 15848906
Drug: Reduced overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced overall treatment time (OTT) of radiotherapy (9.5, 6.5, and 5.5 weeks)
Study: 1683340
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg zotepine
Study: 1683340
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg zotepine
Study: 1683340
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg zotepine
Study: 23053769
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral therapy (COT) including pyrimethamine, sulfadiazine, folinic acid and prednisone
Study: 23053769
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral therapy (COT)
Study: 21770716
Drug: DPSGC 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPSGC 100 mg
Study: 19487635
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin infusion at 1.0 and 2.0 units/h
Study: 7977180
Drug: Group condition
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group condition (G) - received self-help manuals, watched a 20-day televised series, participated in six sessions emphasizing quitting techniques and social support, and monthly peer-led support groups with incentives.
Study: 7977180
Drug: Nongroup condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nongroup condition (NG) - received self-help manuals and watched a 20-day televised series, but no further treatment after the initial phase.
Study: 20819898
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation at 0 mg/kg per day (placebo)
Study: 20819898
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation at 1 mg/kg per day
Study: 20819898
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation at 2 mg/kg per day
Study: 10674681
Drug: Primaquine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (30 mg a day for 14 days)
Study: 10674681
Drug: Artesunate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (200 mg once a day for 3 days) plus primaquine (30 mg a day for 14 days)
Study: 2404389
Drug: Prolonged infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged infusion of intravenous heparin for greater than or equal to 72 hours (group 2)
Study: 29676197
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of strontium ranelate
Study: 21036891
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg three times per day)
Study: 12066084
Drug: Supracervical Foley
Normalized name: CATHETER,FOLEY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supracervical Foley catheter and 100 microg oral doses of misoprostol
Study: 12066084
Drug: Serial 100‐microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial 100‐microg oral doses of misoprostol
Study: 9831997
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride (n = 77) in flexible doses up to 200 mg
Study: 7521313
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 150 mg/day
Study: 7521313
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 600 mg/day
Study: 7521313
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 900 mg/day
Study: 31630035
Drug: Celecoxib (CBX)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (CBX) adjunctive treatment
Study: 16847150
Drug: hsCRP >3
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP >3 mg/L
Study: 27328699
Drug: hsCRP <1
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP <1 mg/L
Study: 24259978
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg AMT before bedtime
Study: 24259978
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Pantoprazole once daily for 4 weeks
Study: 22309474
Drug: 10-week psychosocial
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10-week psychosocial treatment involving parent management training for ADHD and family-based cognitive-behavioral therapy for anxiety.
Study: 22309474
Drug: 10-week psychosocial
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10-week psychosocial treatment
Study: 31764732
Drug: Acetaminophen (Control)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (Control)
Study: 7884951
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of ibuprofen
Study: 7884951
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of ibuprofen
Study: 7884951
Drug: 12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg of acetaminophen
Study: 6453432
Drug: Clearfil Bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clearfil Bonding Agent
Study: 30559054
Drug: Octenilin® wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octenilin® wound gel
Study: 28132813
Drug: Ketanserin (5-HT2AR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (5-HT2AR antagonist)
Study: 25181938
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy and progressive muscle relaxation training plus routine nursing care
Study: 21384392
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss supplement (Curva™) in conjunction with low-level laser treatments
Study: 17013479
Drug: No medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medications (control group)
Study: 15464863
Drug: drugs +
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: drugs + rTMS (1 Hz, 0.6 T, 100 stimuli per day for 7 days, repeated at least twice yearly for 3 years)
Study: 15461603
Drug: drugs only
Approvals — FDA: no, EMA: no, PMDA: no
Description: drugs only
Study: 11417923
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Melatonin
Study: 19419845
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Placebo
Study: 9236640
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg rhRIx
Study: 9236640
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg rhRIx
Study: 9236640
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg rhRIx
Study: 8783319
Drug: Naloxone (opiate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (opiate antagonist)
Study: 25052161
Drug: YXBCM01 granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: YXBCM01 granule (5.5 g twice daily)
Study: 25052161
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy (calcipotriol betamethasone for the first 4 weeks and calcipotriol ointment for the remaining 8 weeks)
Study: 12100060
Drug: prednisolone 30
Normalized name: prednisolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone 30 mg/day
Study: 7717714
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) 600 mg/m2 plus high‐dose l‐leucovorin (l‐LV) 250 mg/m2, given weekly by i.v. injection
Study: 7717714
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) 370 mg/m2 plus high‐dose l‐leucovorin (l‐LV) 100 mg/m2, given simultaneously for 5 consecutive days
Study: 7717714
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) 370 mg/m2 plus low‐dose l‐leucovorin (l‐LV) 10 mg/m2, given with the same schedule as regimen B
Study: 1790311
Drug: Pentacard 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentacard 20 mg tablets
Study: 1790311
Drug: Ismo 20
Normalized name: Ismo 20mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ismo 20 mg tablets
Study: 30826050
Drug: No loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: No loading dose (NLD)
Study: 30826050
Drug: Clopidogrel maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel maintenance therapy
Study: 30826050
Drug: No clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No clopidogrel maintenance therapy
Study: 28827938
Drug: Honey (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey (20 mL)
Study: 10791216
Drug: Mannite solution
Normalized name: Mannit
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannite solution (10%); 2000 mL during the first 2 hours, then 2000 mL per day until no rectal blood observed.
Study: 10791216
Drug: Paromomycine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycine (1 g tid) and lactulose (10 mL tid)
Study: 8876703
Drug: Atamestane 300
Normalized name: Atamestane
DrugBank: Atamestane (DB12194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atamestane 300 mg
Study: 1496141
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy (20 Gy in 10 treatments over 2 weeks)
Study: 26717873
Drug: Nurse-initiated daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-initiated daily verbal reminders
Study: 24727333
Drug: Dexamethasone 0.1
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1 mg/mL
Study: 21054769
Drug: 320/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320/25 mg valsartan/hydrochlorothiazide (HCTZ)
Study: 17425487
Drug: Control (currently
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (currently approved treatment options)
Study: 10540089
Drug: Remifentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil with propofol (target plasma concentration of remifentanil varied while maintaining propofol at 4.5 microg x ml-1)
Study: 18057912
Drug: Clotrimazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (100 mg)
Study: 31082898
Drug: Somatostatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (500 μg bolus followed by 250 μg/h infusion for 5 days)
Study: 21487089
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (atorvastatin 80 mg)
Study: 16954134
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy (pravastatin 40 mg)
Study: 3876325
Drug: sulphamoxole 3200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphamoxole 3200 mg/trimethoprim 640 mg (single dose)
Study: 3876325
Drug: trimethoprim 700
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: trimethoprim 700 mg (single dose)
Study: 3876325
Drug: sulphamoxole 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphamoxole 800 mg/trimethoprim 160 mg (twice daily for five days)
Study: 30052825
Drug: S66913 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S66913 (5 mg, 25 mg, or 100 mg orally per day)
Study: 18049889
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (ganirelix 0.25 mg/d for 3 days)
Study: 18049889
Drug: Control (self-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (self-controlled cycle without GnRH antagonist)
Study: 9828907
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with GnRH analogue leuprolide acetate (0.3 mg/kg im every 28 days) and rhGH (0.1 U/kg/day, sc, 6 days a week) for 30.0 ± 5.2 months
Study: 2894764
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate 50 mg twice a day
Study: 29327548
Drug: TCM synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM synthetic rehabilitation (manipulative therapy, joint mobilization, soaking-washing with Chinese medicinal herbs, functional exercise)
Study: 25531733
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 10 mg/kg as a bolus, 15 minutes before incision
Study: 17158419
Drug: High-fructose diet
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose diet (1.5 g fructose . kg body wt(‐1) . d(‐1) for 4 weeks)
Study: 1582625
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (E) 20‐40 mg daily
Study: 29458318
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care oxygen therapy
Study: 20092401
Drug: Vitamin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin treatment with folic acid and vitamin B12 for 2 months (Group 2, n = 30)
Study: 19909082
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated split-virus influenza vaccine (TIV)
Study: 11571068
Drug: Alcohol‐focused couples
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol‐focused couples therapy
Study: 2881566
Drug: Atracurium (ED95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (ED95 0.23 mg kg‐1)
Study: 27489011
Drug: DPZS (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPZS (7 mg Zn/d)
Study: 19457494
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (40 mL)
Study: 31242943
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (MTX)
Study: 6179339
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of long-term continuous steroid application
Study: 29617743
Drug: Head orthosis
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head orthosis therapy
Study: 2928987
Drug: Sodium excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium excretion
Study: 18789189
Drug: Body oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body oriented psychological therapy (BPT)
Study: 15062138
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or hyperthermia
Study: 15062138
Drug: Interstitial pulsed-dose-rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interstitial pulsed-dose-rate (PDR) brachytherapy
Study: 11032084
Drug: Reference products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference products as per WHO List of International Comparator Pharmaceutical Products (CPP)
Study: 11032084
Drug: Generic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic drugs developed using the CPP
Study: 11032084
Drug: Formulations with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations with maintained safety and efficacy
Study: 9127120
Drug: Blood-volume-pulse biofeedback
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-volume-pulse biofeedback followed by cognitive behavioral therapy (Group I)
Study: 9127120
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy followed by blood-volume-pulse biofeedback (Group II)
Study: 1337291
Drug: Naloxone (0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.015 mg/kg)
Study: 8796815
Drug: Naloxone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (both doses)
Study: 1337291
Drug: Naloxone (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (low dose)
Study: 27098820
Drug: Stepwise implementation
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise implementation administered and monitored in a quarterly rheumatological nurse‐administered set‐up targeting hyperlipidaemia, hypertension, hyperglycaemia, and microalbuminuria
Study: 19079825
Drug: Carers' critical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carers' critical comments (CC) at follow-up
Study: 15824508
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (5 doses of 200 mg weekly)
Study: 10383527
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.d. in H. pylori-negative patients
Study: 6753092
Drug: Flunisolide (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide (topical corticosteroid)
Study: 29410968
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (1 g TXA intravenously)
Study: 29410968
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (3 g TXA in 100 ml saline intra-articularly)
Study: 29410968
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA vs Topical TXA
Study: 25544738
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment for 12 weeks
Study: 25544738
Drug: Dose-escalation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalation intervention after 6 weeks
Study: 15536655
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three techniques (NIR, Laser Doppler, Digital photography)
Study: 8901854
Drug: Alpha-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (50 mg)
Study: 31306433
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for soil-transmitted helminth infection (specific interventions not detailed in the abstract)
Study: 28635026
Drug: ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ixekizumab 80 mg every 4 weeks (IXEQ4W)
Study: 28635026
Drug: ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ixekizumab 80 mg every 12 weeks (IXEQ12W)
Study: 28635026
Drug: ixekizumab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: ixekizumab (any dosage)
Study: 23375005
Drug: Physiotherapy (isometric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy (isometric training of abdominal muscles, diaphragmatic breathing exercises, and abdominal massage during 12 40‐min sessions twice a week) + laxatives
Study: 18678578
Drug: rAAV2‐TNFR:Fc (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV2‐TNFR:Fc (1 x 10(11) DNase resistant particles per ml joint volume)
Study: 17341245
Drug: Receipt of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receipt of pneumococcal vaccine
Study: 10336577
Drug: Clevidipine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevidipine at target dose rates ranging from 0.12 to 48 nmol min‐1 kg‐1
Study: 8760089
Drug: Constant GH
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant GH infusion
Study: 1744358
Drug: Immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (IT) for 3 and 4 years
Study: 1744358
Drug: Non-immunotherapy (non-IT)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-immunotherapy (non-IT)
Study: 27869715
Drug: Inositol-stabilized arginine
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for 14 days
Study: 27869715
Drug: Inositol-stabilized arginine
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for 3 days